VivoSeq
Other

Revumenib

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Revumenib is an early-stage landscape with 0 programs across 1 company. The most active players are Syndax Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Syndax Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
No longer available1 · 33%

Clinical Trials

Trial Activity

Expanded Access Program for Revumenib
No longer available·SSyndax Pharmaceuticals·N/A·NCT05918913
Revumenib in Combination With 7+3 + Midostaurin in AML
Recruiting·RRichard Stone, MD·Phase 1·NCT06313437·22 enrolled
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06284486·8 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)